Home>>Signaling Pathways>> Others>> FAS>>C75

C75

Catalog No.GC34065

C75 is a fatty acid synthase (FASN/FAS) inhibitor with an IC50 of 15.53 μM and has potential therapeutic effects in various cancer models. C75 is also a potent activator of CPT1A.

Products are for research use only. Not for human use. We do not sell to patients.

C75 Chemical Structure

Cas No.: 218137-86-1

Size Price Stock Qty
10mM (in 1mL DMSO)
$85.00
In stock
2mg
$61.00
In stock
5mg
$91.00
In stock
10mg
$147.00
In stock
50mg
$588.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product has been cited by 1 publications

Product Documents

Quality Control & SDS

View current batch:

Protocol

Cell experiment [1]:

Cell lines

HepG 2、SMMC 7721、Hep 3B cells

Preparation method

Cells (5.0 x 106/10 cm dish) were treated with C75 for the indicated time intervals. Control cells received equivalent amounts of DMSO alone. FAS activity of cytoplasmic fractions of cells was measured by fluorescence quantification after exposure to 15 μg/ml C75 for 15 or 30 min.

Reaction Conditions

15 μg/ml ; 15 or 30 min.

Applications

Treatment of cells with C75 (15 μg/ml initial dose) produced significant reductions in FAS activity in HepG2 and Hep3B cells within 15 min, and in SMMC7721 cells within 30 min.

Animal experiment [2]:

Animal models

Twelve-week-old DIO C57BL6J male mice

Preparation method

DIO C57BL6J mice were fed a synthetic diet consisting of 60% calories from fat after weaning. Mice were maintained on a 12-h light-dark cycle at 25°C for 1 week before treatment. C75 and etomoxil were dissolved in RPMI medium 1640 and injected intraperitoneally at the indicated doses. Three mice were treated with C75 (20 mg/kg) on day 0. Subsequent doses were administered as follows: 15 mg/kg on day 2; 10 mg/kg on day 4; 15 mg/kg. On days 6 and 8, four mice received RPMI medium 1640.

Dosage form

10-20 mg/kg; i.p.

Applications

In DIO mice, C75 treatment led to a 50% weight loss and a 32.9% increase in energy production due to fatty acid oxidation

References:

[1] Gao Y , Lin L P .Growth arrest induced by C75, A fatty acid synthase inhibitor, was partially modulated by p38 MAPK but not by p53 in human hepatocellular carcinoma.[J].Cancer Biology & Therapy, 2006, 5(8):978-985.

[2] Thupari JN, et al. C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9498-502.

Background

C75 is a specific inhibitor of fatty acid synthase (FASN/FAS) with moderate inhibitory activity, showing an IC50 value of 15.53 μM[1]. It is used in research on obesity and cancer to explore the connection between fatty acid synthesis, energy metabolism, tumor growth, and survival. C75 is also an effective activator of CPT1A[2].

In vitro, it inhibits PC3 cell growth with a 24-hour IC50 of 35μM and reduces the growth of LNCaP spheroids in a concentration-dependent manner with an IC50 of 50μM[3]. Additionally, C75-mediated CPT 1A activation inhibits EMT, as indicated by reduced migration and α-SMA expression in HK-2 cells[4].

In vivo, C75 injection suppresses fasting-induced c-Fos expression in specific hypothalamic nuclei and reduces mouse feeding by ≥ 95% within 2 hours at a dose of 30 mg/kg[5]. In DIO mice, C75 treatment led to a 50% weight loss and a 32.9% increase in energy production due to fatty acid oxidation[2].

References:

[1] Wang X , Lin J , Chen Y ,et al.Novel fatty acid synthase (FAS) inhibitors: Design, synthesis, biological evaluation, and molecular docking studies[J].Bioorganic & Medicinal Chemistry, 2009, 17(5):1898-1904.

[2] Thupari JN, et al. C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9498-502.

[3] Rae C, et al. Inhibition of Fatty Acid Synthase Sensitizes Prostate Cancer Cells to Radiotherapy. RADIATION RESEARCH 184, 482–493 (2015).

[4] L Peng, C Wang, S Yu, et al. Dysregulated lipid metabolism is associated with kidney allograft fibrosis. Lipids in Health and Disease, 2024(23).

[5] Gao S, et al. Effect of the anorectic fatty acid synthase inhibitor C75 on neuronal activity in the hypothalamus and brainstem. Proc Natl Acad Sci U S A. 2003 May 13;100(10):5628-33.

Chemical Properties

Cas No. 218137-86-1 SDF
Canonical SMILES O=C(C(C1=C)C(CCCCCCCC)OC1=O)O
Formula C14H22O4 M.Wt 254.32
Solubility DMSO : ≥ 83.3 mg/mL (327.54 mM) Storage Store at -20°C
General tips Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month.
To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table

Prepare stock solution
1 mg 5 mg 10 mg
1 mM 3.9321 mL 19.6603 mL 39.3205 mL
5 mM 0.7864 mL 3.9321 mL 7.8641 mL
10 mM 0.3932 mL 1.966 mL 3.9321 mL
  • Molarity Calculator

  • Dilution Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).

Calculate

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Reviews

Review for C75

Average Rating: 5 ★★★★★ (Based on Reviews and 9 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for C75

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.